BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31717736)

  • 21. Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia.
    Argilés JM; Busquets S; Felipe A; López-Soriano FJ
    Int J Biochem Cell Biol; 2005 May; 37(5):1084-104. PubMed ID: 15743680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sarcopenia, cachexia and congestive heart failure in the elderly.
    Zamboni M; Rossi AP; Corzato F; Bambace C; Mazzali G; Fantin F
    Endocr Metab Immune Disord Drug Targets; 2013 Mar; 13(1):58-67. PubMed ID: 23369138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer.
    Chadha AS; Kocak-Uzel E; Das P; Minsky BD; Delclos ME; Mahmood U; Guha S; Ahmad M; Varadhachary GR; Javle M; Katz MH; Fleming JB; Wolff RA; Crane CH; Krishnan S
    Acta Oncol; 2015 Jul; 54(7):971-8. PubMed ID: 25608822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact.
    Prado CM; Cushen SJ; Orsso CE; Ryan AM
    Proc Nutr Soc; 2016 May; 75(2):188-98. PubMed ID: 26743210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pentraxin 3 is an adipose tissue-related serum marker for pancreatic cancer cachexia predicting subsequent muscle mass and visceral fat loss.
    Sato K; Hikita H; Shigekawa M; Kato S; Sasaki Y; Shinkai K; Fukuoka M; Kudo S; Sato Y; Fukumoto K; Shirai K; Myojin Y; Sakane S; Murai K; Yoshioka T; Nishio A; Kodama T; Sakamori R; Tatsumi T; Takehara T
    Cancer Sci; 2022 Dec; 113(12):4311-4326. PubMed ID: 36074525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postdiagnosis Loss of Skeletal Muscle, but Not Adipose Tissue, Is Associated with Shorter Survival of Patients with Advanced Pancreatic Cancer.
    Babic A; Rosenthal MH; Bamlet WR; Takahashi N; Sugimoto M; Danai LV; Morales-Oyarvide V; Khalaf N; Dunne RF; Brais LK; Welch MW; Zellers CL; Dennis C; Rifai N; Prado CM; Caan B; Sundaresan TK; Meyerhardt JA; Kulke MH; Clish CB; Ng K; Vander Heiden MG; Petersen GM; Wolpin BM
    Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2062-2069. PubMed ID: 31533940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer.
    Tamandl D; Paireder M; Asari R; Baltzer PA; Schoppmann SF; Ba-Ssalamah A
    Eur Radiol; 2016 May; 26(5):1359-67. PubMed ID: 26334504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term Clinical Outcomes of Nonoperative Management With Chemoradiotherapy for Locally Advanced Rectal Cancer in the Veterans Health Administration.
    Spiegel DY; Boyer MJ; Hong JC; Williams CD; Kelley MJ; Moore H; Salama JK; Palta M
    Int J Radiat Oncol Biol Phys; 2019 Mar; 103(3):565-573. PubMed ID: 30359718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function.
    Bachmann J; Ketterer K; Marsch C; Fechtner K; Krakowski-Roosen H; Büchler MW; Friess H; Martignoni ME
    BMC Cancer; 2009 Jul; 9():255. PubMed ID: 19635171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma.
    Rollins KE; Tewari N; Ackner A; Awwad A; Madhusudan S; Macdonald IA; Fearon KC; Lobo DN
    Clin Nutr; 2016 Oct; 35(5):1103-9. PubMed ID: 26411749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
    Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
    Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative sarcopenia and post-operative accelerated muscle loss negatively impact survival after resection of pancreatic cancer.
    Choi MH; Yoon SB; Lee K; Song M; Lee IS; Lee MA; Hong TH; Choi MG
    J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):326-334. PubMed ID: 29399990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pioglitazone treatment increases survival and prevents body weight loss in tumor-bearing animals: possible anti-cachectic effect.
    Beluzi M; Peres SB; Henriques FS; Sertié RA; Franco FO; Santos KB; Knobl P; Andreotti S; Shida CS; Neves RX; Farmer SR; Seelaender M; Lima FB; Batista ML
    PLoS One; 2015; 10(3):e0122660. PubMed ID: 25807446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer.
    Griffin OM; Duggan SN; Ryan R; McDermott R; Geoghegan J; Conlon KC
    Pancreatology; 2019 Sep; 19(6):850-857. PubMed ID: 31362865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Skeletal muscle is enriched in hematopoietic stem cells and not inflammatory cells in cachectic mice.
    Berardi E; Aulino P; Murfuni I; Toschi A; Padula F; Scicchitano BM; Coletti D; Adamo S
    Neurol Res; 2008 Mar; 30(2):160-9. PubMed ID: 18397608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rosiglitazone reduces body wasting and improves survival in a rat model of cancer cachexia.
    Trobec K; Palus S; Tschirner A; von Haehling S; Doehner W; Lainscak M; Anker SD; Springer J
    Nutrition; 2014 Sep; 30(9):1069-75. PubMed ID: 24976415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Muscle wasting in cancer and ageing: cachexia versus sarcopenia.
    Argilés JM; Busquets S; Felipe A; López-Soriano FJ
    Adv Gerontol; 2006; 18():39-54. PubMed ID: 16676797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer.
    Lee J; Chang CL; Lin JB; Wu MH; Sun FJ; Jan YT; Hsu SM; Chen YJ
    Clin Cancer Res; 2018 Oct; 24(20):5028-5036. PubMed ID: 29959140
    [No Abstract]   [Full Text] [Related]  

  • 39. Pretreatment C-reactive protein level predicts outcome and patterns of failure after chemoradiotherapy for locally advanced pancreatic cancer.
    Kishi T; Nakamura A; Itasaka S; Shibuya K; Matsumoto S; Kanai M; Kodama Y; Takaori K; Mizowaki T; Hiraoka M
    Pancreatology; 2015; 15(6):694-700. PubMed ID: 26601881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipases and lipid droplet-associated protein expression in subcutaneous white adipose tissue of cachectic patients with cancer.
    Silvério R; Lira FS; Oyama LM; Oller do Nascimento CM; Otoch JP; Alcântara PSM; Batista ML; Seelaender M
    Lipids Health Dis; 2017 Aug; 16(1):159. PubMed ID: 28830524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.